Cardiotoxicity in patients treated with bevacizumab is potentially reversible

Journal of Clinical Oncology

Volumn 29, Issue 18, 2011, Pages

  Hawkes, Eliza A ^a   Okines, Alicia F C ^a   Plummer, Chris ^b   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; PLACEBO; PREDNISONE; RAZOXANE; RITUXIMAB; TRASTUZUMAB; VINCRISTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; ESOPHAGOGASTRIC CANCER; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE FAILURE; HUMAN; HYPERTENSION; LARGE CELL LYMPHOMA; LETTER; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT DURATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG LABELING; EARLY TERMINATION OF CLINICAL TRIALS; EPIRUBICIN; FEMALE; FLUOROURACIL; HEART FAILURE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; META-ANALYSIS AS TOPIC; PACLITAXEL; PREDNISONE; RAZOXANE; REMISSION, SPONTANEOUS; VINCRISTINE;

EID: 79959296552     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.5008     Document Type: Letter

References (16)

1. Choueiri TK, Mayer EL, Je Y, et al: Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 29:632-638, 2011
2. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
3. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
4. Ewer MS, Lippman SM: Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 23:2900-2902, 2005 (Pubitemid 46224107)
5. Ewer MS, Vooletich MT, Durand JB, et al: Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820-7826, 2005 (Pubitemid 46657379)
6. Billingham ME, Mason JW, Bristow MR, et al: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62:865-872, 1978 (Pubitemid 8377880)
7. Mackay B, Ewer MS, Carrasco CH, et al: Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol 18:203-211, 1994 (Pubitemid 24131629)
8. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002 (Pubitemid 34177427)
9. F Hoffman-La Roche: Investor update. http://www.roche.com/investors/ir- update/inv-update-2010-06-03.htm
10. Cunningham D, Smith P, Mouncey P, et al: A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma. J Clin Oncol 27:435s, 2009 (abstr 8506)
11. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979 (Pubitemid 10218041)
12. D'Adamo DR, Anderson SE, Albritton K, et al: Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 23:7135-7142, 2005
13. Ganjoo KN, An CS, Robertson MJ, et al: Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 47:998-1005, 2006
14. Ryberg M, Nielsen D, Skovsgaard T, et al: Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16:3502-3508, 1998 (Pubitemid 28506760)
15. von Minckwitz G, Eidtmann H, Loibl S, et al: Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 22:301-306, 2011
16. Ejlertsen B, Jensen MB, Nielsen KV, et al: HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol 28:984-990, 2010